Drugs / autologous Tcm cellular immunotherapy
autologous Tcm cellular immunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03820310 | May 2018 → Jun 2025 | intrahepatic cholangiocarcinoma | Newish Technology (Beijing) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous Tcm cellular immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03820310 ↗ |
| Modality | Cell therapy | “Autologous cellular immunotherapy is to collect patient's own immune cells and infuse into the patient's body after culture in vitro” NCT03820310 ↗ |